Myeloma 2017 | Optimism for the use of liquid biopsies in multiple myeloma
In this insightful panel discussion at the Myeloma 2017 meeting in Edinburgh, UK, Marc Raab, MD from the University of Heidelberg, Heidelberg, Germany, Niels Weinhold, PhD from the UAMS Myeloma Institute, Little Rock, AR, Irene Ghobrial, MD from the Dana-Farber Cancer Institute, Boston, MA, Andrew Spencer, MD, PhD from Monash University, Melbourne, Australia and Rodger Tiedemann, PhD, ChB, MB from the Princess Margaret Cancer Centre, Toronto, Canada, discuss whether we should be moving away from the use of bone marrow biopsies in multiple myeloma (MM), in the wake of advancing liquid biopsies. The panel discuss the advantages of liquid biopsies, including the ability to take multiple samples and hence better reflect the clonal heterogeneity of patients. The latter leads the discussion onto the importance of precision medicine for MM patients.
Get great new content delivered to your inboxSign up